Short Interest in Provectus Biopharmaceuticals, Inc. (OTCMKTS:PVCT) Drops By 99.2%

Provectus Biopharmaceuticals, Inc. (OTCMKTS:PVCT) saw a significant drop in short interest during the month of November. As of November 15th, there was short interest totalling 500 shares, a drop of 99.2% from the October 31st total of 65,600 shares. Based on an average trading volume of 595,800 shares, the days-to-cover ratio is presently 0.0 days.

Provectus Biopharmaceuticals Stock Up 7.1 %

Shares of PVCT stock opened at $0.12 on Friday. Provectus Biopharmaceuticals has a 1-year low of $0.04 and a 1-year high of $0.22. The company has a 50-day moving average of $0.11 and a two-hundred day moving average of $0.12.

About Provectus Biopharmaceuticals

Provectus Biopharmaceuticals, Inc, a clinical-stage biotechnology company, engages in developing immunotherapy medicines based on halogenated xanthenes in the United States. The company's lead molecule is rose bengal sodium (RBS). Its clinical development programs include PV-10 for the treatment of stage III and IV melanoma and different types of liver cancers; PH-10 for the treatment of psoriasis and atopic dermatitis, and skin inflammation; and PV-305 for the treatment of infectious keratitis.